Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05081375
Other study ID # 2019-071
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date December 16, 2019
Est. completion date November 2, 2023

Study information

Verified date April 2024
Source Valleywise Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

All trauma patients receive Lovenox or other prophylactic medication to prevent deep vein clots from forming. For the trauma patients with orthopedic injuries requiring surgery there is controversy over safety and efficacy when prophylaxis is started preoperatively vs postoperatively. This study is to evaluate both approaches for safety in terms of bleeding events during and 24 hours after surgery as well as preventing deep vein clot formation. This will be a randomized double blinded study using Lovenox or placebo as the medications given preoperatively. Postoperative Lovenox will be given to both groups per routine regime.


Description:

This study will be conducted in an Intensive Care Unit (ICU) and Operating Room (OR) of Valleywise Health Medical Center. The study population will include adult subjects age ≥ 18 years of age, that require surgery for management of their traumatic long bone and/or pelvic fractures. A total of 60 evaluable subjects will be enrolled in this pilot safety study, with a 1:1 randomization into each group. It is anticipated that approximately 70 patients will need to be consented to reach 60 evaluable subjects. Subjects recruited for study participation must meet all study enrollment criteria prior to being enrolled in the study. Patients who meet inclusion / exclusion criteria will be invited to participate in the study. As feasible, the patient or his/her representative will be approached for enrollment in the study and asked to provide informed consent for participation. Written informed consent will be obtained for all subjects by an investigator or delegate prior to enrollment in the study. All subjects meeting inclusion/exclusion criteria will be randomized to either enoxaparin or placebo. Patients will be monitored for bleeding complications from the time of test article administration to 24 hours post-surgery. Subjects will be monitored for the development of DVT and/or PE through-out their hospitalization. Subjects will be randomized to either 30 mg enoxaparin Sub Cutaneous (SQ) of 0.9% Sodium Chloride (NaCl) placebo SQ. Randomization will be 1:1, using a masked randomization list. Study personnel and the treatment team will be blinded to the randomization assignment. The Clinical Research Manager and pharmacy staff will be un-blinded and will not participate in study assessments. The two groups will be treated as follows: Treatment Group: Enoxaparin 30mg/0.3ml SQ will be given within 12 hours prior to surgery. If surgery should be delayed longer than 12 hours following the initial dose a second dose will be given to ensure uninterrupted dosing. If the patient is already on Lovenox 12 hours prior to surgery, no doses will be skipped. Placebo Group Normal Saline (0.9%) 0.3 ml SQ will be given within 12 hours prior to surgery If surgery should be delayed longer than 12 hours following the initial dose a second dose of normal saline will be given to ensure the appearance of uninterrupted dosing in order to maintain the blind. If the patient is already being given Enoxaparin 12 hours prior to surgery, the dose 12 hours prior to surgery will be substituted with normal saline. Both groups Will receive routine administration of Enoxaparin 12 hours following surgery Will be monitored at 12 hours and 24 hours post procedure for any evidence of deep vein thrombosis (DVT) or pulmonary embolism (PE) formation. Will be monitored during surgery, at 12 hrs and 24 hrs post-operatively for any bleeding events. A bleeding event is present if one or more of the following are present: A drop of 3mg/dl or more in hemoglobin, Transfusion of blood product, Intervention/surgery for bleeding (hematoma, hemorrhage) The following information will be collected and recorded: Demographics: name, age, race, ethnicity, height, weight, physical exam 1. Medical history 2. Acute trauma history 3. Surgical data: procedure, length of surgery, estimated blood loss 4. Lab results 5. Imaging results 6. Bleeding complications 7. DVT and PE events 8. Outcome data (length of stay, ICU days, vent days, complications, disposition, etc.) 9. Unanticipated problems


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date November 2, 2023
Est. primary completion date November 2, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - Traumatic injury of long bones or pelvis requiring surgical intervention - Admission to the ICU Exclusion Criteria: - Age < 18 years - Intracranial hemorrhage - Direct admit to OR without prior ICU admission - Pregnancy - Prisoner - Chronic Kidney Disease requiring dialysis or a glomerular filtration rate (GFR) or creatinine clearance requiring a decrease in Enoxaparin dosage - Presence of DVT prior to study drug dose

Study Design


Intervention

Drug:
Enoxaparin Injectable Product
Not holding prophylaxis dose prior to surgical procedure
Sodium chloride
Holding prophylaxis dose of Enoxaparin replacing with placebo

Locations

Country Name City State
United States Valleywise Health Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
Valleywise Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate Bleeding Complications Related to DVT chemoprophylaxis Evaluate the rate of bleeding complications related to DVT chemoprophylaxis after administering DVT chemoprophylaxis vs holding doses within 12 hours of surgery in patients with long bones and/or pelvic fractures requiring surgical intervention. From the time of study drug administration to 24 hours post-operation
Primary Evaluate Other Complications (besides bleeding) Related to DVT chemoprophylaxis Evaluate the rate of other complications (besides bleeding) Related to DVT chemoprophylaxis after administering DVT chemoprophylaxis vs holding doses within 12 hours of surgery in patients with long bones and/or pelvic fractures requiring surgical intervention. From the time of study drug administration to 24 hours post-operation
Secondary Incidence of DVT and PE Recording any incidence of deep vein thrombosis or pulmonary embolism From the time of study drug administration to hospital discharge up to 3 months
Secondary study duration Record the time required to complete study enrollment goals From Institutional Review Board approval to date of last subject completion up to 2 years
Secondary Assess feasibility of a larger trial with respect to study design Assess a superiority study design using the rates of development of DVT/PE. Duration of the study up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT04588350 - Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery N/A
Completed NCT00985920 - Topical Tranexamic Acid for Total Knee Arthroplasty Phase 4
Terminated NCT03954314 - DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery Phase 3
Completed NCT04040023 - Patient Blood Management in Cardiac Surgery N/A
Not yet recruiting NCT05379530 - TEG Use in Children Undergoing Procedures With High Anticipated Blood Loss N/A
Withdrawn NCT05672407 - The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery Phase 4
Recruiting NCT03740438 - Modeling of the Hemoglobin Drop in the Uncomplicated Postoperative Course
Completed NCT05708690 - Topical Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery Phase 4
Completed NCT04143373 - Effect of Warm Saline Irrigation on Bleeding in Mandibular Third Molar Surgery N/A
Completed NCT02996006 - New Techniques to Reduce Intra-operative Bleeding During Complex Liver Resection N/A
Completed NCT03313583 - French One Day Survey in 2011 - Knowing Our Population of Labile Blood Products Recipients N/A
Completed NCT03952546 - To Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer in Primary Unilateral Total Knee Arthroplasty N/A
Active, not recruiting NCT03426839 - Haemostasis Management of Abdominal Aortic Procedures N/A
Completed NCT05780125 - Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness Phase 2
Recruiting NCT06164769 - Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery N/A
Completed NCT04025736 - Arthroscopic Shoulder Surgery With Administration of Intravenous Tranexamic Acid N/A
Recruiting NCT02580227 - Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures Phase 4
Terminated NCT03160170 - Efficacy of Suction Enabled Retraction Device N/A
Not yet recruiting NCT06414031 - Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery Phase 3
Withdrawn NCT03340116 - Measurement of Blood Volume Loss During Burn Surgery